Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
Dec 24, 2024 · The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
New Oral Weight Loss Drugs: Where Are We and What's Next?
Jun 5, 2024 · Now that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an insatiable market for weight loss drugs, biotech and pharmaceutical companies are roaring ahead with ...
Scribe - Medscape
Record your patient visit. Scribe records your entire patient visit, letting you focus on your patient. Simply place your phone on your desk during the visit and easily pause and resume with one tap.
Medscape – Help | CME
3 days ago · How Do I Participate in CME/CE Activities? Select an online activity available for CME, nursing CE, or pharmacy CE credit. Read the goal and/or learning objectives.
Cardiology News & Opinion – theheart.org - Medscape
3 days ago · Cardiology : Welcome to theheart.org | Medscape Cardiology, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles ...
Medscape Salary Explorer
2 days ago · Medscape's Salary Explorer provides physician salary data in an interactive format. Filter by experience level, location, and more for your personalized report.
FDA Approves 'Female Viagra' Flibanserin ( Addyi ) - Medscape
Aug 18, 2015 · Flibanserin (Addyi) — also known as "Female Viagra" or "Pink Viagra" — will be marketed by Sprout Pharmaceuticals.It is approved to treat premenopausal women. The nonhormonal therapy — a 5 ...
Post-Exertional Malaise in Fatiguing Diseases: What to Know
Dec 20, 2024 · Identifying the phenomenon of post-exertional malaise (PEM) in patients with fatiguing conditions is critical because it necessitates a far more cautious approach to exercise, experts said.
New Data: The Most Promising Treatments for Long COVID
Nov 27, 2024 · Long COVID is a symptom-driven disease, meaning that with no cure, physicians primarily treat the symptoms their patients are experiencing. Effective treatments for long COVID remain elusive ...
American College of Rheumatology (ACR) 2024 Annual Meeting
From Medscape Rheumatology Coverage from the American College of Rheumatology (ACR) 2024 Annual Meeting November 14 - 19, 2024; Washington, D.C.